4 Investor presentation First nine months of 2024 Strategic Aspirations 2025 | High Progress towards zero environmental impact • Overall CO 2 e emissions 1 increased by 34% compared to the first nine months of 2023 Adding value to society • Medical treatment provided to 41.5 million people living with diabetes and 1.8 million living with obesity • Reached more than 59,000 children in the Changing Diabetes ® in Children programme Being recognised as a sustainable employer • Share of women in senior leadership positions has increased to 41% from 40.5% end of September 2023 Purpose and sustainability (ESG) Commercial execution Diabetes value market share increased by 0.6%-points to 33.9% 2 Obesity care sales of DKK 43.7 billion (+44% at CER) Rare disease sales of DKK 12.9 billion (+3% at CER) 1 Scope 1, 2 and 3 2 MAT (Moving annual total) value market share CER: Constant exchange rates; CO 2 e: CO 2 equivalents; CV: Cardiovascular; CVOT: CV outcomes trial; EU: European Union Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth
Download PDF file